Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin-17A-trageting oligonucleotide - Matinas BioPharma

Next Previous
X
Search
Drug Profile

Interleukin-17A-trageting oligonucleotide - Matinas BioPharma

Alternative Names: IL-17A-targeting-oligonucleotide-Matinas BioPharma

Latest Information Update: 16 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Matinas BioPharma
  • Class Antipsoriatics; Oligonucleotides
  • Mechanism of Action Interleukin 17 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis

Most Recent Events

  • 27 Dec 2023 Preclinical trials in Psoriasis in USA (PO) prior to December 2023
  • 27 Dec 2023 Pharmacodynamics data from a preclinical study in Psoriasis released by Matinas Biopharma
  • 07 Jul 2022 Matinas Biopharma has patent protection for cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent in the US, Australia, Japan and Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top